BACKGROUND: The liver is the most common site of metastases for colorectal cancer, and combined resection with systemic chemotherapy is the most effective strategy for survival. The aim of this article is to provide a comprehensive summary on four hot topics related to chemotherapy and surgery for colorectal liver metastases (CLM), namely: (1) chemotherapy-related liver injuries: prediction and impact, (2) surgery for initially unresectable CLM, (3) the emerging role of RAS mutations, and (4) the role of hepatic arterial infusion of chemotherapy (HAIC). SUMMARY AND KEY MESSAGES: (1) The use of chemotherapy before liver resection for CLM leads to drug-specific hepatic toxicity, which negatively impacts posthepatectomy outcomes. (2) Curative liver resection of initially unresectable CLM following conversion chemotherapy should be attempted whenever possible, provided that a safe future liver remnant volume is achieved. (3) For CLM, RAS mutation status is needed to guide the use of targeted chemotherapy with anti-epithelial growth factor receptor (EGFR) agents, and is a major prognostic factor that may contribute to optimize surgical strategy. (4) HAIC agents increase the rate of objective response and the rate of complete pathological response.

Passot, G., Soubrane, O., Giuliante, F., Zimmitti, G., Goéré, D., Yamashita, S., Vauthey, J. N., Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases, <<LIVER CANCER>>, 2016; 6 (1): 72-79-79. [doi:10.1159/000449349] [http://hdl.handle.net/10807/94281]

Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases

Olivier; Giuliante;Felice; Zimmitti;
2016

Abstract

BACKGROUND: The liver is the most common site of metastases for colorectal cancer, and combined resection with systemic chemotherapy is the most effective strategy for survival. The aim of this article is to provide a comprehensive summary on four hot topics related to chemotherapy and surgery for colorectal liver metastases (CLM), namely: (1) chemotherapy-related liver injuries: prediction and impact, (2) surgery for initially unresectable CLM, (3) the emerging role of RAS mutations, and (4) the role of hepatic arterial infusion of chemotherapy (HAIC). SUMMARY AND KEY MESSAGES: (1) The use of chemotherapy before liver resection for CLM leads to drug-specific hepatic toxicity, which negatively impacts posthepatectomy outcomes. (2) Curative liver resection of initially unresectable CLM following conversion chemotherapy should be attempted whenever possible, provided that a safe future liver remnant volume is achieved. (3) For CLM, RAS mutation status is needed to guide the use of targeted chemotherapy with anti-epithelial growth factor receptor (EGFR) agents, and is a major prognostic factor that may contribute to optimize surgical strategy. (4) HAIC agents increase the rate of objective response and the rate of complete pathological response.
Inglese
Passot, G., Soubrane, O., Giuliante, F., Zimmitti, G., Goéré, D., Yamashita, S., Vauthey, J. N., Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases, <<LIVER CANCER>>, 2016; 6 (1): 72-79-79. [doi:10.1159/000449349] [http://hdl.handle.net/10807/94281]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/94281
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact